Renaissance Capital logo

Janux Therapeutics Priced, Nasdaq: JANX

Preclinical biotech developing novel T cell engagers for solid tumors.

Industry: Health Care

Latest Trade: $18.66 0.00 (0.0%)

First Day Return: +47.9%

Return from IPO: +9.8%

Industry: Health Care

We are an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), and our lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome (CRS), (ii) on-target, healthy tissue toxicities and (iii) poor pharmacokinetics (PK) leading to short half-life. We are using our TRACTr platform technology to engineer product candidates designed to overcome these limitations. We are developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of our programs currently in the preclinical or discovery stage. We expect to submit at least two Investigational New Drug application (IND) submissions by the end of 2022. We expect to initially seek regulatory approval for our product candidates as later lines of therapy in patients with cancer.
more less
IPO News for Janux Therapeutics
more
IPO Data
IPO File Date 05/19/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.4
Deal Size ($mm) $194
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/10/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.4
Deal Size ($mm) $194
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters La Jolla, CA
Founded 2017
Employees 16
Website www.januxrx.com